Literature DB >> 35384641

Palovarotene: First Approval.

Sheridan M Hoy1.   

Abstract

Palovarotene (Sohonos™) is an orally bioavailable selective retinoic acid receptor (RAR)γ agonist being developed by Ipsen for the reduction of heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP). By binding to RARγ, palovarotene inhibits bone morphogenetic protein and SMAD 1/5/8 signalling: interfering with these pathways prevents chondrogenesis and ultimately HO by permitting normal muscle tissue repair or regeneration to occur. Palovarotene received its first approval on 21 January 2022 to reduce the formation of HO in adults and children aged 8 years and above for females and 10 years and above for males with FOP in Canada. This article summarizes the milestones in the development of palovarotene leading to this first approval.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35384641     DOI： 10.1007/s40265-022-01709-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  6 in total

Review 1.  Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.

Authors:  Kelly L Wentworth; Umesh Masharani; Edward C Hsiao
Journal:  Br J Clin Pharmacol       Date:  2019-01-06       Impact factor: 4.335

Review 2.  Current and Emerging Therapeutic Options for the Management of Rare Skeletal Diseases.

Authors:  Oliver Semler; Mirko Rehberg; Nava Mehdiani; Miriam Jackels; Heike Hoyer-Kuhn
Journal:  Paediatr Drugs       Date:  2019-04       Impact factor: 3.022

3.  Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.

Authors:  Benjamin M Wheatley; Katherine E Cilwa; Devaveena Dey; Ammar T Qureshi; Jonathan G Seavey; Allison M Tomasino; Erin M Sanders; Wesley Bova; Cynthia A Boehm; Masahiro Iwamoto; Benjamin K Potter; Jonathan A Forsberg; George F Muschler; Thomas A Davis
Journal:  J Orthop Res       Date:  2017-11-16       Impact factor: 3.494

4.  Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.

Authors:  Sayantani Sinha; Kenta Uchibe; Yu Usami; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Bone       Date:  2016-02-15       Impact factor: 4.398

5.  Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.

Authors:  Gabriel J Pavey; Ammar T Qureshi; Allison M Tomasino; Cary L Honnold; Danett K Bishop; Shailesh Agarwal; Shawn Loder; Benjamin Levi; Maurizio Pacifici; Masahiro Iwamoto; Benjamin K Potter; Thomas A Davis; Jonathan A Forsberg
Journal:  Bone       Date:  2016-06-28       Impact factor: 4.398

Review 6.  Retinoid Agonists in the Targeting of Heterotopic Ossification.

Authors:  Robert J Pignolo; Maurizio Pacifici
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.